Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 7.9%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX)’s share price fell 7.9% during trading on Wednesday . The stock traded as low as $0.50 and last traded at $0.51. 187,369 shares were traded during trading, a decline of 87% from the average session volume of 1,417,318 shares. The stock had previously closed at $0.55.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating on shares of Kiora Pharmaceuticals in a research report on Wednesday, March 27th.

Kiora Pharmaceuticals Stock Down 7.9 %

The business’s fifty day moving average is $0.63 and its 200 day moving average is $0.60.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A number of hedge funds have recently modified their holdings of KPRX. Renaissance Technologies LLC bought a new stake in shares of Kiora Pharmaceuticals in the 1st quarter worth approximately $58,000. Boothbay Fund Management LLC bought a new stake in Kiora Pharmaceuticals during the 4th quarter valued at $40,000. Acadian Asset Management LLC bought a new stake in Kiora Pharmaceuticals during the 1st quarter valued at $70,000. Dimensional Fund Advisors LP bought a new stake in Kiora Pharmaceuticals during the 1st quarter valued at $41,000. Finally, Walleye Capital LLC bought a new stake in Kiora Pharmaceuticals during the 2nd quarter valued at $162,000. Institutional investors own 76.97% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.